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Abstract : The ACTH stimulation test is used to diagnose adrenal insufficiency (AI). This study evaluated the 
diagnostic performance of serum delta cortisol from ACTH stimulation tests and determined appropriate cut-off 
levels of serum 30-minute delta cortisol for the diagnosis of AI, allowing a reduction in the number of 60-minute 
cortisol tests. A 6-year retrospective study in 471 patients was conducted. The performance of the serum delta 
cortisol in diagnosing AI was assessd using a multivariable logistic regression model and the area under ROC 
curves (AuROC). Both serum 30-minute and 60-minute delta cortisol demonstrated equally high diagnostic accu-
racy for AI (AuROC for LDT : 0.91 vs 0.90 ; HDT : 0.91 vs 0.92, respectively). The 30-minute delta cortisol test was 
chosen to develop proposed diagnostic cut-off levels due to its  simplicity. The proposed lower cut-off level for 
30-minute delta cortisol was Δ < 1.8 µg/dL for both LDT and HDT. The upper cut-off levels were Δ > 11.8 µg/dL for 
LDT and Δ > 10.5 µg/dL for HDT. These cut-off levels yielded high sensitivity and specificity > 90%. The 30-minute 
serum delta cortisol using the proposed cut-off levels provides diagnostic performance for AI equal to that of the 
60-minute test and is more convenient, requires less time, less invasive and is cost-saving. 67 : 95-101, February, 
2020
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INTRODUCTION
 
Various measures have been employed in the diagnosis of ad-
renal insufficiency (AI). The most common procedure in clinical 
practice is the ACTH stimulation test. According to the current 
guideline of the Endocrine Society, the standard dose is 250 µg of 
ACTH (HDT) with serum cortisol measured at 30 minutes and/
or 60 minutes (1). Peak cortisol levels below 18 µg/dL (500 nmol/L) 
at 30 and/or 60 minutes (assay-specific) indicate AI. However, 
in medical institutions where ACTH is in short supply, using 
low dose (1 µg) ACTH (LDT) instead of 250 µg may be a viable 
option (1). If the ACTH stimulation test is not accessible, serum 
morning cortisol of < 5 µg/dL (< 140 nmol/L) may be employed as 
a preliminary test to suggest AI (1). 
Multiple studies have proposed simple alternative measure-
ments to diagnose AI, e.g., serum basal cortisol level with an 
upper level of  > 16.3 µg/dL (450 nmol/L) and lower level of < 3.6 
µg/dL (100 nmol/L) (2). Other studies have proposed new cut-off 
values for serum morning cortisol as well as suggesting addi-
tional diagnostic variables including the indications for ACTH 
stimulation testing and a history of glucocorticoid use to help 
identify the occurrence of AI (3). Other studies have suggested 
performing only a 30-minute cortisol test after ACTH injection 
(4, 5).
The peak time for measurement of serum cortisol, at 30 or 60 
minutes, using LDT and HDT is still inconclusive (6, 7). Per-
forming only a 30- or a 60-minute cortisol test cannot definitively 
diagnose AI and can potentially result in over-diagnosis of AI. A 
previous study reported that 24% of patients would be misclas-
sified as having AI if only the 30-minute cortisol test were per-
formed because they attained peak serum cortisol at 60 minutes, 
while with only the 60-minute test, only 9% of patients would be 
wrongly classified as AI (8). Using the difference between serum 
basal cortisol at 0 minutes (baseline) and at 30 minutes after 
ACTH (delta cortisol) stimulation instead of the absolute value 
of cortisol might provide an accurate diagnosis while reducing 
the quantity and frequency of blood drawn as well as saving time 
and reducing costs. 
The objectives of our study were a) to compare the diagnostic 
accuracy of 30 and 60 minutes serum cortisol for the diagnosis 
of AI and b) to determine the upper and lower cut-off levels of 
serum 30 minute delta cortisol for the diagnosis of AI catego-
rized by the dose of ACTH used in the stimulation tests. 
MATERIALS AND METHODS
This 6-year retrospective study during the period of January 
2010-January 2016 was conducted at the Endocrine and Metab-
olism Unit of Chiang Mai University Hospital, Thailand using 
data retrieved from electronic hospital medical records. The 
study protocol was approved by the Faculty of Medicine Ethics 
Committee, Chiang Mai University. The study protocol, inclu-
sion and exclusion criteria have been previously mentioned and 
has been used in a previous study (9).
Data collected included patient demographics, indications for 
administration of ACTH stimulation tests, biochemical data ob-
tained within 3 months prior to or following ACTH stimulation 
tests and the results of ACTH stimulation tests. When more 
than one test had been performed on a patient, only the first test 
was included in the study. 
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ACTH stimulation testing protocol
Following the protocol of our institution, patients who had 
serum 0800 h cortisol between 3-17.9 µg/dL and were therefore 
suspected of having AI were given ACTH stimulation tests to 
confirm the AI diagnosis. This group of patients included those 
with evidence of pituitary or hypothalamic diseases (e.g. adeno-
ma, hypophysitis, empty sella syndrome, infiltrative disease) 
based on MRI imaging ; those with evidence of adrenal gland 
diseases identified from CT imaging (e.g. post-adrenalectomy, 
infiltrative disease, adrenal gland metastasis) ; those with a 
history of glucocorticoids use or use of other medications adulter-
ated with glucocorticoids ; and those having signs and/or symp-
toms of AI or biochemical suggestion of AI. Only LDT (1 µg) was 
used during January 2010-March 2014 as there was an ACTH 
shortage in Thailand ; HDT was employed from April 2014-Jan-
uary 2016. Patients receiving glucocorticoids or other traditional 
medicine suspected of containing glucocorticoids were instructed 
to withhold those substances at least 24-48 hours before test-
ing. All tests were performed at the outpatient clinic between 
0900 h-1300 h by medical nurses. In the test, serum basal cor-
tisol at 0 minute was determined. That was followed by ACTH 
administered intravenously, either 1 µg or 250 µg, after which 
serum cortisol at 30 and 60 minutes were determined. The 1 µg 
ACTH ampules were prepared by pharmacists under sterile con-
ditions. The 250 µg ampules of ACTH were diluted with normal 
saline and stored at 2-8°C. Ampules were used within 60 days 
(1, 10). Serum cortisol assay was performed by electrochemilu-
minescence immunoassay (ECLIA) using Elecsys® (Roche Diag-
nostic, Laval, Quebec) with the intra- and inter-assay coefficients 
of variation for serum cortisol of < 10%.
Definitions
AI was defined as a peak serum cortisol level < 18 µg/dL at 
either 30 or 60 minutes after ACTH stimulation testing (1). 
Serum morning cortisol was measured from samples specifically 
drawn at 0800 h ; serum basal cortisol samples were drawn any 
time before ACTH was administered and prior to the dynamic 
tests. Serum 30- and 60-minute delta cortisol levels were defined 
as the difference between the value of basal cortisol (0 minute) 
and cortisol level at 30 and 60 minutes, respectively. A history 
of traditional medicine use was described as a history of using 
any herbal or traditional medicine suspected of being  adulter-
ated with glucocorticoids. Signs and symptoms of AI included 
fatigue, weight loss, syncope, intractable nausea/vomiting and 
orthostatic hypotension which were documented in the patient’s 
medical chart. Biochemical investigation results suggestive of 
AI were defined as hyponatremia (serum sodium < 135 mEq/L), 
hypoglycemia (serum glucose < 55 mg/dL), hyperkalemia (serum 
potassium > 4.5 mEQ/L), hypereosinophilia (total eosinophil 
levels > 1,500/µL of blood) and lymphocytosis (total lymphocytes 
> 4,000/µL of blood). 
Statistical analysis
Data were analyzed by STATA version 15.1 (Stata Corp., 
College Station, TX, USA). Categorical variables are presented 
as counts and percentages ; continuous variables as means and 
standard deviation (SDs). For inferential statistics, categorical 
variables were analyzed by Fisher exact test and continuous 
variables by t-test or Mann-Whitney U test. The associations 
between AI and 30- and 60-minute serum delta cortisol levels 
was analyzed using a univariable and multivariable logistic re-
gression model and are reported as odds ratios (ORs). The areas 
under the ROC curve (AuROC) of the model were plotted to 
discriminate diagnostic performance of each value categorized 
by the ACTH dosage used in the stimulation tests. Sensitivity, 
specificity, positive predictive value (PPV), negative predictive 
value (NPV), likelihood ratio of positive results (LHR+), likeli-
hood ratio of negative results (LHR-) as well as the number of 
true positives (TP), false negatives (FN), false positives (FP) 
and true negatives (TN) are reported for each proposed cut-off 
point. Proposed cut-off levels were set at an intervals of 0.9 µg/
dL (25 nmol/L). The cut-off value which gave the highest sen-
sitivity and the lowest number of FN results was classified as 
the appropriate upper cut-off level while those with the highest 
specificity with the lowest number of FP results were classified 
as the appropriate lower cut-off level. The statistical significance 
level was set as two-tailed with a P-value < 0.05.
RESULTS
Baseline characteristics
Baseline characteristics are depicted in Table 1. Of the 471 
patients (226 male and 245 females) included in the study who 
were at risk for AI, 23.8% (n = 112/471) were identified as having 
AI. The mean age of the AI group was significantly higher than 
the normal adrenal response group (non-AI group). The most 
common indication for ACTH stimulation testing was the pres-
ence of AI symptoms (33.7%, n = 159/471). Diagnosis of AI was 
signficiantly higher in patients for whom a history of exogenous 
steroid use, post-pituitary surgery or pituitary tumor was the 
indication for testing. No significant difference in the prevalence 
of AI was observed between LDT and HDT. Among the other 
biochemical values measured, significantly lower serum albu-
min and serum creatinine and a significantly higher incidence 
of hyperkalemiawere observed in patients with AI than those in 
the non-AI group. 
Demographic and biochemical data categorized by LDT and 
HDT and by peak serum cortisol at 30 and 60 minutes after 
ACTH stimulation tests are shown in Supplementary Table 1 
and 2. The majority of patients in both the LDT and HDT groups 
showed peak serum cortisol at 60 minutes after ACTH stimula-
tion testing. A significantly higher number of patients with peak 
serum cortisol at 60 minutes was found in the HDT group than 
in the LDT group (91.9%, n = 262/285 and 79.1%, n = 147/186, 
respectively). In the LDT group, if only a 30-minute cortisol level 
were performed on the patients with peak cortisol at 60 minutes, 
6.8% (n = 10/147) of the patients with normal adrenal function 
would have been incorrectly classified as having AI. In the HDT 
group, if only 30-minute cortisol levels were acquired, approxi-
mately 13.7% (n = 36/262) of the patients with normal adrenal 
function would have been misclassified as having AI. The box-
plot for serum basal, 30- and 60-minute delta cortisol categori-
azed by LDT and HDT is depicted in Supplementary Figure 1.
Serum delta cortisol levels and predictive performance for adrenal 
insufficiency
Based on multivariable analysis adjusted for age, sex, serum 
albumin, cholesterol, creatinine and ACTH dose, serum delta 
cortisol at both 30 and 60 minutes after ACTH stimulation tests 
demonstrated a significant association with AI. All ORs were 
less than 1, which suggests the lower the delta cortisol, the high-
er the likelihood of having AI (Table 2). 
Evaluation of diagnostic performance by AuROC found serum 
delta cortisol at 60 minutes had similar performance with serum 
delta cortisol at 30 minutes for both LDT and HDT (p = 0.877 
and 0.687, respectively). The AuROCs for 30- and 60-minute 
delta cortisol were higher than 0.8 for both (Figure 1 and Table 
3).  
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Table 1　Demographic and biochemical factors categorized by adre-
















Body Weight (mean ± SD) (kg) 58.2 ± 13.3 61.4 ± 16.1 0.058
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Baseline SBP (mean ± SD)
 (mmHg)
120.4 ± 22.6 121.4 ± 19.9 0.653
Baseline DBP (mean ± SD) 
(mmHg)
71.5 ± 15.9 73.7 ± 12.7 0.137








 (mean ± SD) (µg/dL)
7.9 ± 2.9 9.6 ± 3.3 < 0.001
Serum Basal Cortisol
 (mean ± SD) (µg/dL)
6.2 ± 3.2 10.9 ± 5.4 < 0.001
Cortisol at 30 Min
 (mean ± SD) (µg/dL)
11.7 ± 3.8 23.9 ± 5.9 < 0.001
Cortisol at 60 Min
 (mean ± SD) (µg/dL)
6.5 ± 3.5 15.7 ± 5.5 < 0.001
30-Min Delta Cortisol
 (mean ± SD) (µg/dL)
5.5 ± 2.8 13.1 ± 4.8 < 0.001
60-Min Delta Cortisol
 (mean ± SD) (µg/dL)
6.5 ± 3.5 15.7 ± 5.6 < 0.001
Serum Albumin 
(mean ± SD) (g/dL)
3.6 ± 0.8 3.9 ± 0.6 < 0.001
Serum Cholesterol 
(mean ± SD) (mg/dL)
177.9 ± 58.0 185.6 ± 58.0 0.445
Serum Creatinine 
(mean ± SD) (mg/dL)
1.1 ± 1.0 0.9 ± 0.7 0.038
Hypoglycemia, N (%)  2 (1.8) 12 (3.3) 0.397
Hyponatremia, N (%) 86 (85.1) 264 (88.3) 0.409
Hyperkalemia, N (%) 117 (32.6) 27 (24.1) 0.089
Hypereosinophilia, N (%) 2 (2.2) 3 (1.1) 0.420
Lymphocytosis, N (%) 6 (6.7) 17 (6.1) 0.857
SBP : Systolic blood pressure
DBP : Diastolic blood pressure
Supplementary Table 1　Demographic data categorized by low 











Adrenal insufficiency, N (%) 38 (20.4) 74 (25.9) 0.168
Peak cortisol at 30 minutes, N (%)




262 (91.9) < 0.001







124 (43.4) < 0.001
Body Weight (mean ± SD) (kg) 60.2 ± 12.2 60.9 ± 15.1 0.638

















































(mean ± SD) (mmHg)
121.6 ± 20.9 121.0 ± 20.4 0.782
Baseline DBP 
(mean ± SD) (mmHg)
74.1 ± 11.9 72.7 ± 14.5 0.305
Serum Morning Cortisol 
(mean ± SD) (µg/dL)
9.3 ± 3.5 9.7 ± 3.2 0.531
Serum Basal Cortisol 
(mean ± SD) (µg/dL)
10.2 ± 6.1 9.5 ± 4.7 0.166
Cortisol at 30 Min 
(mean ± SD) (µg/dL)
22.6 ± 7.9 20.1 ± 7.3 < 0.001
Cortisol at 60 Min 
(mean ± SD) (µg/dL)
24.1 ± 8.5 22.7 ± 8.3 0.072
30-Min Delta Cortisol 
(mean ± SD) (µg/dL)
12.4 ± 5.7 10.6 ± 5.2 < 0.001
60-Min Delta Cortisol 
(mean ± SD) (µg/dL)
14.3 ± 6.8 13.3 ± 6.3 0.256
Serum Albumin 
(mean ± SD) (g/dL)
3.7 ± 0.7 3.9 ± 0.6 0.002
Serum Cholesterol 
(mean ± SD) (mg/dL)
193.4 ± 65.8 181.7 ± 54.1 0.035
Serum Creatinine 
(mean ± SD) (mg/dL)
0.9 ± 0.7 0.9 ± 0.9 0.758
SBP : Systolic blood pressure
DBP : Diastolic blood pressure
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Figure 1　AuROC comparing between serum delta cortisol at 30 
and 60 minutes. A) low dose ACTH stimulation test, B) high dose 
ACTH stimulation test
Supplementary Figure 1　Boxplot of serum basal cortisol, serum 
delta cortisol at 30 and 60 minutes. A) low dose ACTH stimulation 
test, B) high dose ACTH stimulation test
Table 2　Univariable and multivariable model for serum delta corti-





P-value Odd ratio (95% CI) P-value
Serum delta cortisol 
at 30 minutes 0.98 (0.97-0.99) < 0.001 0.98 (0.97-0.99) < 0.001
Serum delta cortisol 
at 60 minutes 0.98 (0.98-0.99) < 0.001 0.98 (0.98-0.99) < 0.001
*Adjusted for age, sex, serum albumin, cholesterol, creatinine and 
ACTH dose





Serum delta cortisol at 
30 minutes vs Serum del-
ta cortisol at 60 minutes
0.91 vs 0.90 (0.88-0.94) vs (0.88-0.93) 0.877
HDT
Serum delta cortisol at 
30 minutes vs Serum del-
ta cortisol at 60 minutes
0.91 vs 0.92 (0.89-0.94) vs (0.90-0.94) 0.687
LDT : Low dose ACTH stimulation test
HDT : High dose ACTH stimulation test
Supplementary Table 2　Demographic data categorized by peak 
serum cortisol at 30 and 60 minutes after ACTH stimulation tests
Characteristics
Peak cortisol 
at 30 min 
(n = 62)
Peak cortisol 
at 60 min 
(n = 409)
P-value
Adrenal insufficiency, N (%) 22 (35.5) 90 (22.0) 0.020








Body Weight (mean ± SD) (kg) 63.4 ± 18.7 60.2 ± 14.9 0.147





























　-　Other Pituitary Hormonal 
　　　Deficiencies


















(mean ± SD) (mmHg) 122.9 ± 19.2 120.9 ± 20.8 0.469
Baseline DBP 
(mean ± SD) (mmHg) 74.6 ± 15.1 73.0 ± 13.3 0.375
Serum Morning Cortisol 
(mean ± SD) (µg/dL) 8.7 ± 3.6 9.2 ± 3.2 0.261
Serum Basal Cortisol 
(mean ± SD) (µg/dL) 9.8 ± 5.8 9.7 ± 5.4 0.930
Serum Albumin 
(mean ± SD) (g/dL) 3.8 ± 0.6 3.9 ± 0.7 0.757
Serum Cholesterol 
(mean ± SD) (mg/dL) 201.3 ± 52.7 182.2 ± 58.2 0.034
Serum Creatinine 
(mean ± SD) (mg/dL) 0.8 ± 0.3 0.9 ± 0.8 0.197
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Proposed cut-off levels for 30-minute serum delta cortisol
As the diagnostic accuaracy of delta 30- and 60-minute cor-
tisol was similar, only delta cortisol at 30 minutes was used in 
the analysis for proposed cut-off levels. Data for each cut-off level 
categorized by LDT and HDT are depicted in Table 4. 
For LDT, the lower cut-off for 30-minute delta cortisol to rule 
in AI which gave the highest specificity (99.3%) was Δ < 1.8 µg/
dL, while the upper cut-off to rule out AI which gave the high-
est sensitivity (97.4%) was Δ > 11.8 µg/dL. Delta cortisol levels 
were below the cut-off in 1.6% of cases (n = 3/186), while they 
were above the cut-off in 42.5% of cases (n = 79/186). Similarly, 
for HDT the lower cut-off for 30-minute delta cortisol to rule in 
AI which gave the highest specificity (99.4%) was Δ < 1.8 µg/
dL, while the upper cut-off to rule out AI which had the highest 
sensitivity (98.6%) was Δ > 10.5 µg/dL. Delta cortisol levels were 
below the cut-off in 3.2% of cases (n = 9/285), while levels were 
above the cut-off in 49.5% of cases (n = 141/285) in HDT. The 
proposed upper and lower cut-off levels resulted in only one FP 
and one FN, respectively. Other proposed cut-off levels for LDT 
and HDT also gave high sensitivity and specificity (around 90%) 
(Table 4). If the proposed serum delta cortisol cut-off levels were 
used, 58% (n = 108/186) of the LDT and 53% (n = 151/285) of the 
HDT patients would have been appropriately categorized.
When the above mentioned cut-off levels were used in the pa-
tients who attained peak serum cortisol at 60 minutes which is 
the group concerning for AI over-diagnosis, increased sensitivity 
and specificity were observed. With LDT using the lower cut-off 
level of Δ < 1.8 µg/dL, the specificity was 100% ; the upper cut-
off level of Δ > 11.8 µg/dL also had a sensitivity of 100%. With 
HDT, the lower cut-off level of Δ < 1.8 µg/dL revealed a specificity 
of 99.5%, while the upper cut-off level of Δ > 10.5 µg/dL gave a 
similar sensitivity result of 98.6%. If only a 30-minute cortisol 
levels had been acquired during LDT, n = 10/147 or, in HDT, 
n = 36/262 patients would have been incorrectly classified as 
having AI. If the upper and lower cut-off levels had been used 
with both LDT and with HDT, all patients in both groups would 
have been correctly identified as non-AI.
DISCUSSION
The present study highlights the important finding that 
serum delta cortisol at both 30 and 60 minutes after ACTH stim-
ulation tests can predict the occurrence of AI with a high degree 
of diagnostic accuracy. No significant differences in diagnostic 
accuracy between the two groups were observed. For the health 
care practitioner, using only 30-minute cortisol to calculate the 
delta cortisol levels offers the benefits of increased convenience, 
being less invasiveness and requiring less time while providing 
high specificity and sensitivity for ruling in and ruling out AI. 
Both 30- and 60-minute delta cortisol demonstrated ‘excellent’ 
overall diagnostic accuracy with AuROC of between 90-100% 
(11). The justification for using the “delta” value of serum cortisol 
after ACTH stimulation tests is a study which demonstrated that 
using the absolute single-time serum cortisol value, especially at 
30 minutes, may increase the number of false positives for AI (8, 
12). Thus using delta cortisol levels rather than absolute levels 
of cortisol may have high performance in AI diagnosis. The 
use of serum delta cortisol in AI diagnosis has been reported in 
multiple reports but those results have been inhomogeneous. For 
example, a study by Struja et al. stated that delta cortisol does not 
offer any added information compared to baseline cortisol alone. 
They found that delta cortisol was inferior to basal cortisol with 
AUCs of 0.85 (95% CI : 0.81-0.89) and 0.88 (95% CI : 0.83- 0.92), 
respectively (2). Delta cortisol has also been proposed for use in 
critically ill patients. Using serum delta cortisol after HDT in 
critically-ill patients with a cut-off level of Δ < 9 µg/dL after peak 
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LDT : Low dose ACTH stimulation test    
HDT : High dose ACTH stimulation test 
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serum cortisol can help diagnose critical illness-related cortico-
steroid-induced adrenal insufficiency conditions (13). However, 
this concept can be applied only in a critically ill setting.
Specific patterns in peak serum cortisol were demonstrated 
in the present study. Although most of the patients attained 
peak cortisol at 60 minutes, which is in agreement with a study 
by Cartaya et al. (8), we postulated that using only a 30-minute 
cortisol level could facilitate AI diagnosis as it would be less 
time-consuming, simpler and less expensive as only two blood 
samples are required (basal cortisol and 30-minutes serum 
cortisol). However, using only a 30-minute cortisol level raises 
concern regarding AI overdiagnosis in 6-14% of patients, par-
ticulary in patients who had undergone HDT. In order to reduce 
the incidence of false positives that could result in inappropriate 
treatment with corticosteroids and which, in turn, could lead 
to multiple long-term complications, we proposed upper and 
lower cut-offs for serum delta cortisol levels. Although one study 
reported that mean cortisol levels with LDT and HDT at 30 min-
utes were not different (12), other studies have reported different 
accuracy levels and time variabilities between LDT and HDT 
(14, 15). For that reason, this study used different 30-minute 
delta cortisol cut-off values for LDT and for HDT.
With both LDT and HDT, if the proposed 30-minute delta 
cortisol had been utilized all patients who formerly fell into the 
AI over-diagnosed group when only a 30-minute cortisol was 
employed would have been correctly identified as having no 
AI.  These results suggest that our porposed cut-off levels and 
utilizing only 30-minute serum cortisol testing can help reduce 
the incidence of AI over-diagnosis. For LDT in particular, multi-
ple studies have recommended 30-minute cortisol values as the 
test of choice to evaluate AI (4, 5, 16).  However, data on the use 
of HDT and only 30-minute cortisol are still inconclusive. Only 
one study has reported benefits from using 30-minute cortisol in 
HDT to diagnose AI, while other studies have reported no diag-
nostic value and a very high false positive rate using this value 
in isolation (17-19). If our upper and lower proposed cut-off levels 
for 30-minute delta cortisol levels were employed with all the pa-
tients included in this study, approximately 58% of the LDT and 
53% of the HDT patients would have been appropriately catego-
rized. This would reduce by more than half the need to perform 
other cortisol tests or to draw specimens at 60 minutes. For those 
reasons, we recommend performing only a 30-minute cortisol 
level and calculating delta cortisol levels. If serum 30-minute 
cortisol levels are undiagnosed or if delta cortisol levels fall 
between the upper and lower cut-off levels (intermediate range), 
then 60-minute cortisol may be determines. This proposed mea-
sure provides markedly high diagnostic performance for AI and 
could be easily used in normal clinical practice.
The reason for choosing the upper cut-off level which gave the 
highest sensitivity to rule-out AI was that AI is a potentially 
lethal condition if left untreated and thus requires timely diag-
nosis. There is a need for a tool which provides high sensitivity to 
minimize the number of false negative AI diagnoses. Likewise, 
the lower cut-off values to rule in AI were the values which gave 
the highest specificity with the lowest incidence of false positives. 
Treating patients with glucocorticoids who may not need these 
medications may cause harm, e.g., physical and metabolic chang-
es such as osteoporosis.  
The present study has multiple strengths. We found that the 
use of delta cortisol after ACTH stimulation testing yielded excel-
lent accuracy in AI diagnosis. In particular, 30-minute cortisol 
is beneficial in terms of increased convenience as well as saving 
time and expense. The proposed cut-off for 30-minute cortisol 
could make these findings more widely applicable in acutal prac-
tice. As most of the peaks in serum cortisol after an ACTH stim-
ulation test occur at 60 minutes, the likelihood of having a false 
positive diagnosis of AI is high if only 30-minute cortisol level 
testing is performed. The cut-off levels that we have presented 
could diminish these diagnostic errors.  Confounding variables 
in the multivariable analysis model were appropriately adjusted 
for, including serum albumin, cholesterol and creatinine levels 
which various studies have demonstarted to be associated with 
serum cortisol interference (20-22). Another strength is the large 
sample size with an adequate power of > 80% (23). 
We acknowledge some limitations in this study. The proposed 
cut-off levels were based on the Roche diagnostic ECLIA assay 
for cortisol which has been reported as one of the three most 
commonly used cortisol assays in United Kingdom (24). Previ-
ous report has demonstrated that in a comparison of five moden 
immunoassays for serum cortisol post-ACTH stimulation tests 
using mass spectrometry as a reference method, the serum corti-
sol responses in healthy volunteers were assay- and gender-spe-
cific (25). As an example of the diversity of response, in healthy 
individuals, the post-ACTH cortisol levels have been reported to 
ranged from 19.6 µg/dL (542 nmol/L) in females with the Archi-
tect assay to 27.9 µg/dL (772 nmol/L) in males with the Roche 
Diagnostic assay (25). Thus, the results in the present study may 
not be directly applicable for institutes using assays other than 
the Roche diagnostic ECLIA assay. These results should be ap-
plied only with the subgroup with indeterminate serum 0800 h 
cortisol levels between 3-17.9 µg/dL as that is the only population 
included in the analysis. The gold standard for diagnosing AI, 
i.e. the insulin tolerance test, was not used in this study. The 
ACTH stimulation test cannot diagnose patients with partial 
or recent secondary AI, so the AI status of those patients cannot 
be determined based solely on the ACTH stimulation test. The 
specific time at which the ACTH stimulation test was performed 
was not documented. Only the period (0900 h-1300 hr) was 
recorded.  As levels of serum basal cortisol exhibit a diurnal 
variation, it may have affected the delta cortisol levels in those 
whose ACTH stimulation tests were conducted after noon (26). 
In the present study, ACTH level tests were not performed in all 
patients who had been diagnosed with AI. The causes of AI in 
the present study were based solely on clinical suggestions. he 
population included in this study were varied in indications of 
testing, therefore the results may not be relevant for some sub-
groups although the heterogeneity of the sample does suggest a 
level of generalizability. 
CONCLUSIONS
Serum delta cortisol, especially the 30-minute delta cortisol 
level from ACTH stimulation tests, can facilitate AI diagnosis. 
The cut-off levels proposed for 30-minute delta cortisol yield high 
accuracy. Using the proposed values of 30-minute delta cortisol 
levels offers increased simplicity for healthcare practitioners and 
the patients, although 60-minute serum cortisol level may be 
needed for almost half of the patients. Further prospective study 
is needed to comfirm and validate these results. 
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